Neuroinflammation in frontotemporal dementia
- PMID: 31324897
- DOI: 10.1038/s41582-019-0231-z
Neuroinflammation in frontotemporal dementia
Abstract
Frontotemporal dementia (FTD) refers to a group of progressive neurodegenerative disorders with different pathological signatures, genetic variability and complex disease mechanisms, for which no effective treatments exist. Despite advances in understanding the underlying pathology of FTD, sensitive and specific fluid biomarkers for this disease are lacking. As in other types of dementia, mounting evidence suggests that neuroinflammation is involved in the progression of FTD, including cortical inflammation, microglial activation, astrogliosis and differential expression of inflammation-related proteins in the periphery. Furthermore, an overlap between FTD and autoimmune disease has been identified. The most substantial evidence, however, comes from genetic studies, and several FTD-related genes are also implicated in neuroinflammation. This Review discusses specific evidence of neuroinflammatory mechanisms in FTD and describes how advances in our understanding of these mechanisms, in FTD as well as in other neurodegenerative diseases, might facilitate the development and implementation of diagnostic tools and disease-modifying treatments for FTD.
Similar articles
-
Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging.J Neuroinflammation. 2015 May 29;12:108. doi: 10.1186/s12974-015-0236-5. J Neuroinflammation. 2015. PMID: 26022249 Free PMC article. Review.
-
Recent advances in the imaging of frontotemporal dementia.Curr Neurol Neurosci Rep. 2012 Dec;12(6):715-23. doi: 10.1007/s11910-012-0317-0. Curr Neurol Neurosci Rep. 2012. PMID: 23015371 Free PMC article. Review.
-
Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia.J Clin Invest. 2017 Sep 1;127(9):3250-3258. doi: 10.1172/JCI90607. Epub 2017 Jul 24. J Clin Invest. 2017. PMID: 28737506 Free PMC article. Review.
-
Imaging and fluid biomarkers in frontotemporal dementia.Nat Rev Neurol. 2017 Jul;13(7):406-419. doi: 10.1038/nrneurol.2017.75. Epub 2017 Jun 16. Nat Rev Neurol. 2017. PMID: 28621768 Review.
-
Glial cells and adaptive immunity in frontotemporal dementia with tau pathology.Brain. 2021 Apr 12;144(3):724-745. doi: 10.1093/brain/awaa457. Brain. 2021. PMID: 33527991
Cited by
-
Prevalence of Concomitant Pathologies in Parkinson's Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms.J Parkinsons Dis. 2024;14(1):35-52. doi: 10.3233/JPD-230154. J Parkinsons Dis. 2024. PMID: 38143370 Free PMC article. Review.
-
Small molecule C381 targets the lysosome to reduce inflammation and ameliorate disease in models of neurodegeneration.Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2121609119. doi: 10.1073/pnas.2121609119. Epub 2022 Mar 8. Proc Natl Acad Sci U S A. 2022. PMID: 35259016 Free PMC article.
-
Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries.Front Neurol. 2021 Jun 24;12:663407. doi: 10.3389/fneur.2021.663407. eCollection 2021. Front Neurol. 2021. PMID: 34248820 Free PMC article.
-
Sleep Characteristics and Cerebrospinal Fluid Progranulin in Older Adults: The CABLE Study.Neurotox Res. 2021 Jun;39(3):764-773. doi: 10.1007/s12640-020-00326-6. Epub 2021 Jan 14. Neurotox Res. 2021. PMID: 33443646
-
Pterostilbene Attenuates Cocultured BV-2 Microglial Inflammation-Mediated SH-SY5Y Neuronal Oxidative Injury via SIRT-1 Signalling.Oxid Med Cell Longev. 2020 Aug 4;2020:3986348. doi: 10.1155/2020/3986348. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32831997 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
